Prostate

HCRN-GU23-626

Hispanic/Latino and non-Hispanic BlAck patients treated with niRaparib and abiraterone acetate plus prednisone for Metastatic hOrmone sensitive prostate cancer with deleterious homologous recombinatioN repair alterations: a phase II, open label studY (HARMONY)  
Status
Cancer Types
Prostate
Locations

A randomized, double-blind, placebo-controlled phase II study of testosterone replacement in men with asymptomatic castrate-resistant prostate cancer (PC)

Status
Cancer Types
Prostate
Locations

A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune)

Status
Cancer Types
Prostate
Locations

A phase 2 study of cabozantinib and nivolumab in metastatic castration-resistant prostate cancer (CANOPY)

Status
Cancer Types
Prostate
Locations

PACIFIC trial: A randomized phase II study of apatorsen and abiraterone in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) who have had PSA progression while receiving abiraterone (ABI)

Status
Cancer Types
Prostate
Locations

Combination therapy with enzalutamide and the poly (ADP-ribose) polymerase-1 (PARP1) inhibitor niraparib in castration-resistant prostate cancer (CRPC)

Status
Cancer Types
Prostate
Locations

The Borealis-2 clinical trial: A randomized phase 2 study of OGX-427 (Apatorsen) plus docetaxel versus docetaxel alone in relapsed/refractory metastatic urothelial cancer

Status
Cancer Types
Prostate
Locations

Prognostic value of suppressed markers of bone turnover (BTO) after 6 months of androgen deprivation therapy (ADT) in prostate cancer

Status
Cancer Types
Prostate
Locations

A Multicenter Phase II Study of Pemetrexed for the Treatment of Hormone Refractory Prostate Cancer (HRPC) with Reduced Folate Carrier 1 (RFC1) Pharmacogenetic Analysis

Status
Cancer Types
Prostate
Locations

Second-line pemetrexed (P) for the treatment of hormone refractory prostate cancer (HRPC)

Status
Cancer Types
Prostate
Locations

Serum proteomic profiling can distinguish androgen sensitive prostate cancer patients from those with androgen resistant disease

Status
Cancer Types
Prostate
Locations

A Multicenter Randomized Phase II Study of Docetaxel (D) plus Vinorelbine (VRB) and Docetaxel plus Estramustine (EMP) in Combination for the Treatment of Hormone Refractory Prostate Cancer (HRPC)

Status
Cancer Types
Prostate
Locations

Improved Survival for Patients with Hormone-Refractory Prostate Cancer Receiving Estramustine-Based Antimicrotubule Therapy

Status
Cancer Types
Prostate
Locations

Phase II Study of Weekly Vinorelbine and Estramustine for Hormone Refractory Prostate Cancer (HRPC)

Status
Cancer Types
Prostate
Locations

A Phase III Trial of Vinblastine Versus Vinblastine plus Estramustine Phosphate for Metastatic Hormone-refractory Prostate Cancer (HRPC)

Status
Cancer Types
Prostate
Locations

A Prospective Randomized Trial of Cyclophosphamide Versus Cyclophosphamide plus Adriamycin plus Methotrexate in Hormone Refractory Prostate Cancer

Status
Cancer Types
Prostate
Locations

Randomized Phase II Study of Docetaxel, Vinorelbine, and Estramustine in Combination in Hormone-Refractory Prostate Cancer with Pharmacogenetic Survival Analysis

Status
Cancer Types
Prostate
Locations

Phase III Trial of Cyclophosphamide Versus Cyclophosphamide, Doxorubicin and Methotrexate in Hormone-Refractory Prostatic Cancer

Status
Cancer Types
Prostate
Locations

Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer

Status
Cancer Types
Prostate
Locations

A Phase II Hoosier Oncology Group Study of Vinorelbine and Estramustine Phosphate in Hormone Refractory Prostate Cancer

Status
Cancer Types
Prostate
Locations

A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC)

Status
Cancer Types
Prostate
Locations

Failure to suppress markers of bone turnover on first line hormonal therapy for metastatic prostate cancer is associated with shorter time to skeletal related event

Status
Cancer Types
Prostate
Locations

Weekly Paclitaxel and Gemcitabine in Advanced Transitional-Cell Carcinoma of the Urothelium: A Phase II Study

Status
Cancer Types
Prostate
Locations

HCRN-GU19-385

Phase II Trial of Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer (PLANE-PC)
Status
Open to Accrual
Cancer Types
Prostate
Locations

HCRN-GU20-436

NePtune: A Phase 2 Study of Neoadjuvant PARP Inhibition followed by Radical Prostatectomy in Patients with Unfavorable Intermediate-Risk or High-Risk Prostate Cancer with BRCA1/2 Gene Alterations
Status
Cancer Types
Prostate
Locations

HCRN-GU21-517

A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer (CANOPY)
Status
Cancer Types
Prostate
Locations

BTCRC-GU19-404

A Single Arm, Phase I/II Trial of Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men with Localized, High Risk Prostate Cancer Big Ten Cancer Research Consortium BTCRC-GU19-404
Status
Closed
Cancer Types
Prostate
Locations

HCRN-GU14-202

Combined Targeting of the Androgen Receptor in Metastatic Castrate-Resistant Prostate Cancer with Enzalutamide and the Poly (ADP-Ribose) Polymerase [PARP] Inhibitor Niraparib
Status
Closed
Cancer Types
Prostate
Locations

GU13-170

Androgen Deprivation Therapy With or Without Radium-223 Dichloride in Patients With Newly Diagnosed Metastatic Prostate Cancer With Bone Metastases: Hoosier Cancer Research Network GU13-170
Status
Closed
Cancer Types
Prostate
Locations

GU12-159

The Pacific Clinical Trial: A Randomized Phase II Study Evaluating OGX-427 in Patients With Metastatic Castrate-Resistant Prostate Cancer (MCRPC)Who Have Prostate-Specific Antigen (PSA) Progression While Receiving Abiraterone: Hoosier Oncology Group GU12-159
Status
Closed
Cancer Types
Prostate
Locations

GU07-124

A Phase II Study of Neoadjuvant Dasatinib plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
Status
Closed
Cancer Types
Prostate
Locations

GU03-67

A Phase II Study of Pemetrexed (Alimta) as Second-Line Therapy for Hormone Refractory Prostate Cancer: Hoosier Oncology Group GU03-67
Status
Closed
Cancer Types
Prostate
Locations

GU02-41

A Phase III, Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients with Metastatic Prostate Cancer Commencing Hormonal Therapy
Status
Closed
Cancer Types
Prostate
Locations

GU00-9

A Multicenter Randomized Phase II Study of Docetaxel plus Vinorelbine and Doxetacel plus Estramustine in Combination for Hormone Refractory Prostate Cancer
Status
Closed
Cancer Types
Prostate
Locations

HCRN-GU98-1

Phase II Study of Vinorelbine plus Estramustine in Metastatic Hormone-Refractory Prostate Cancer
Status
Closed
Cancer Types
Prostate
Locations

HCRN-GU97-1

Phase II Study of Diethylstilbestrol in Metastatic Prostate Cancer
Status
Closed
Cancer Types
Prostate
Locations

HCRN-GU93-1

A Phase III Study of Vinblastine vs Vinblastine plus Estramustine for Metastatic Hormone Refractory Prostatic Cancer
Status
Closed
Cancer Types
Prostate
Locations

HCRN-GU90-2

Phase II Study of Flutamide Plus Interferon Alpha-2b in Metastatic Hormone Resistant Prostate Cancer
Status
Closed
Cancer Types
Prostate
Locations

HCRN-HOG-02

Phase III Randomized Comparison of Cyclophosphamide vs Cyclophosphamide + Adriamycin + Methotrexate for Stage IV Hormone Resistant Prostatic Cancer
Status
Closed
Cancer Types
Prostate
Locations